Crenolanib is active against models of drug-resistant FLT3-ITD - Positive acute myeloid leukemia

Blood

Volumn 122, Issue 22, 2013, Pages 3607-3615

  Zimmerman, Eric I ^a   Turner, David C ^a   Buaboonnam, Jassada ^a   Hu, Shuiying ^a   Orwick, Shelley ^a   Roberts, Michael S ^a   Janke, Laura J ^a   Ramachandran, Abhijit ^b   Stewart, Clinton F ^a   Inaba, Hiroto ^a   Baker, Sharyn D ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Office of the Chairman and Chief Executive Officer Coscend Communications Solutions LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; CRENOLANIB; FLT3 LIGAND; IMATINIB; PONATINIB; QUIZARTINIB; SORAFENIB; STAUROSPORINE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; NICOTINAMIDE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ACUTE MYELOID LEUKEMIA; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENETICS; LEUKEMIA, MYELOID, ACUTE; MUTATION; NONOBESE DIABETIC MOUSE; SCID MOUSE; TANDEM REPEAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MUTATION; NIACINAMIDE; PHENYLUREA COMPOUNDS; PIPERIDINES; PROTEIN KINASE INHIBITORS; TANDEM REPEAT SEQUENCES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888263107     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-513044     Document Type: Article

References (35)

1. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369-377.
2. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al; AML Committee of the International BFM Study Group. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16): 3187-3205.
3. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.
4. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484-495.
5. Gamis AS, Alonzo TA, Perentesis JP, Meshinchi S; COG Acute Myeloid Leukemia Committee. Children’s Oncology Group’s 2013 blueprint for research: acute myeloid leukemia. Pediatr Blood Cancer. 2013;60(6):964-971.
6. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854-4860.
7. Fröhling S, Schlenk RF, Breitruck J, et al; AML Study Group Ulm. Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372-4380.
8. Ravindranath Y. Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Curr Opin Oncol. 2003;15(1):23-35.
9. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59-66.
10. Baker SD, Zimmerman EI, Wang YD, et al. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia [published online ahead of print August 22, 2013]. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-13-1323.
11. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010;116(24):5089-5102.
12. Man CH, Fung TK, Ho C, et al. Sorafenib treatment of FLT3-ITD(1) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood. 2012;119(22):5133-5143.
13. Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012; 485(7397):260-263.
14. Weisberg E, Sattler M, Ray A, Griffin JD. Drug resistance in mutant FLT3-positive AML. Oncogene. 2010;29(37):5120-5134.
15. Heinrich MC, Griffith D, McKinley A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2012;18(16):4375-4384.
16. AROG Pharmaceuticals. Investigator’s brochure. Crenolanib besylate (CP-868,596-26). Dallas, TX: AROG Pharmaceuticals LLC; 2011:1-115.
17. Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29(11): 1046-1051.
18. Knapper S. The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opin Investig Drugs. 2011;20(10):1377-1395.
19. Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia. 2012;26(10): 2176-2185.
20. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol. 2006;2(7):358-364.
21. Wodicka LM, Ciceri P, Davis MI, et al. Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol. 2010;17(11):1241-1249.
22. Smith CC, Lasater EA, Mccreery M, et al. Crenolanib (CP-868,596) is a potent and selective type I FLT3 inhibitor that retains activity against AC220 resistance-causing FLT3 kinase domain mutations [abstract]. Blood. 2012;120(21). Abstract 141.
23. Lewis NL, Lewis LD, Eder JP, et al. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009;27(31): 5262-5269.
24. Gao C, Zhang W, Jacamo R, et al. Combination of crenolanib with sorafenib produces synergistic pro-apoptotic effects in FLT3-ITD-inhibitor-resistant acute myelogenous leukemias with FLT3 mutations [abstract]. Blood. 2012;120(21). Abstract 3591.
25. Smith CC, Lasater EA, Zhu X, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013;121(16):3165-3171.
26. Hu S, Niu H, Inaba H, et al. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst. 2011;103(11):893-905.
27. Moore AS, Faisal A, Gonzalez de Castro D, et al. Selective FLT3 inhibition of FLT3-ITD1 acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia. 2012;26(7): 1462-1470.
28. Galanis A, Rajkhowa T, Muralidhara C, Ramachandran A, Levis M. Crenolanib is a highly potent, selective, FLT3 TKI with activity against D835 mutations. Blood. 2012;120(21):1341. [abstract]
29. Galanis A, Rajkhowa T, Muralidhara C, Ramachandran A, Levis M. Crenolanib: a next generation FLT3 inhibitor. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; March 31-April 4, 2012; Chicago, IL. Abstract 3660.
30. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14): 2984-2992.
31. Weisberg E, Roesel J, Furet P, et al. Antileukemic effects of novel first- and second-generation FLT3 inhibitors: structure-affinity comparison. Genes Cancer. 2010;1(10):1021-1032.
32. Rossi F, Yozgat Y, de Stanchina E, et al. Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res. 2010;8(9):1271-1283.
33. Gleixner KV, Peter B, Blatt K, et al. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica. 2013;98(9): 1450-1457.
34. Bradeen HA, Eide CA, O’Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108(7):2332-2338.
35. Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA. 2009;106(5):1542-1547.